Wyeth  2Q Revenues: $5.9 billion (+5%)   2Q Earnings: $1.1 billion (-6%) YTD Revenues: $11.7 billion (+6%) YTD Earnings: $2.3 billion (-5%) Comments: Pharmaceutical sales were $5.0 billion (+5%), due to Effexor, Enbrel, Prevnar, and Zosyn sales, as well as the favorable foreign exchange, offset, in part, by lower sales of Protonix due to generic competition. Effexor sales in the quarter were $1.0 billion (+5%) and $2.0 billion YTD (+9%). Prevnar sales were $691 million (+9%) and ...